PNPLA3 targeted GalNAc-AIMer - WaVe life Sciences
Latest Information Update: 18 Nov 2024
Price :
$50 *
At a glance
- Originator WaVe life Sciences
- Class Amines; Amino sugars; Drug conjugates; Hepatoprotectants; Oligonucleotides; Pyrrolidines
- Mechanism of Action Gene expression modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Liver disorders
Most Recent Events
- 30 Oct 2024 Preclinical in Liver disorders in USA (Parenteral) prior to October 2024 (WaVe life Sciences pipeline, October 2024)
- 30 Oct 2024 Pharmacodynamics data from a preclinical studies in Liver disorders released by WaVe life Sciences
- 30 Oct 2024 WaVe life Sciences plans a first in human clinical trial for Non-alcoholic-steatohepatitis (Parenteral)